We’re building DarkTides in public.
Updates, drops, discussions, and direct access happen in our Telegram.
Join here ⤵️
https://t.co/dlZKR6BnNf
Website is in bio.
Two peptides. Completely different mechanisms.
Researchers keep pairing them anyway.
BPC-157 works locally — upregulating growth factor receptors at the injury site itself.
TB-500 works systemically — regulating actin, driving cell migration, promoting angiogenesis across tissue types.
One signals the repair. One recruits the resources.
That's why they show up together.
The GLP space has a hierarchy.
GLP-1: changed everything.
Dual agonism: changed it again.
Triple agonism: researchers are still processing the data.
Reta hits GLP-1, GIP, and glucagon receptors at the same time. That's not incremental. That's a different class of compound entirely.